Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Polycystic kidney disease

26.01.2006


NIH and PKD Foundation launch HALT-PKD treatment trials



The National Institutes of Health (NIH) and the PKD Foundation have launched two treatment trials for autosomal dominant polycystic kidney disease (ADPKD). The common inherited disorder is characterized by cysts in the kidneys and other organs, high blood pressure, and aneurysms (bulges in blood vessels, which may burst) in the brain. Symptoms usually appear between the ages of 30 and 40 and include back and side pain and headaches. About half of ADPKD patients eventually develop kidney failure and require dialysis or a kidney transplant. The first Halt Progression of Polycystic Kidney Disease (HALT-PKD) patient enrolled last week at Emory University in Atlanta, one of seven recruitment sites (www.pkd.wustl.edu/pkd-tn).

"Decades of clinical and basic studies by NIH and others have delivered this exciting opportunity for translational research," says Catherine M. Meyers, M.D., a kidney specialist who directs HALT-PKD at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "Naturally, we appreciate the PKD Foundation’s invaluable guidance and support."


PKD Foundation President and CEO Dan Larson applauded the start of the trials. "PKD families are eager to learn of any potential benefits," says Larson. "Their hope and the hope of the PKD Foundation is that this will be a step toward finding a cure for PKD and improving the care and treatment of those it affects."

Carefully controlling blood pressure and using ACE-inhibitors or ARBs significantly delays or prevents kidney disease and failure from diabetes and other causes by reducing protein in the urine and preventing damage to the small blood vessels in the kidneys. Earlier trials of these treatments in PKD were not definitive, possibly because a small number of patients were involved.

Over the next 2 years, HALT-PKD will recruit more than 1,000 people with ADPKD and treat them for up to 4 years at centers in Atlanta, Boston, Cleveland, Denver, Kansas City, Kansas, and Rochester, Minnesota. The two trials will compare standard therapy using an angiotensin-converting enzyme inhibitor (ACE-inhibitor) to intensive therapy using both an ACE-inhibitor and an angiotensin receptor blocker (ARB). Patients will receive a device for measuring blood pressure at home, clinic visits, lab tests, and study medications at no charge. They will also have their kidney function estimated using a standard blood test measurement called eGFR and other measures to track progression of kidney disease.

HALT-PKD Study A, for people 15 to 49 years of age with early disease (eGFR >60), will also compare standard (120-130/70-80 mm Hg) and low (95-110/60-75 mm Hg) blood pressure targets and measure changes in cyst and kidney size using a Magnetic Resonance Imaging method developed by NIDDK’s Consortium for Radiologic Imaging Studies of PKD. Study B, for people 18 to 64 and more advanced disease (eGFR 30-60), will track the time it takes eGFR to drop by 50 percent, the need for kidney failure treatment, and patient deaths.

PKD affects an estimated 500,000 people, about 90 percent of whom have ADPKD. In 2003, 23,000 people with cystic kidney disease (mostly PKD) received dialysis or a kidney transplant, making it this country’s fourth leading cause of kidney failure. While genetic testing for ADPKD can help determine whether a family member can safely donate a kidney, testing can’t predict onset of symptoms or severity of the disease, which also increases the risk of heart attacks, strokes and early death compared to the general population.

Mary Harris | EurekAlert!
Further information:
http://www.nih.gov
http://www.pkd.wustl.edu/pkd-tn

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

17.01.2017 | Materials Sciences

Smart homes will “LISTEN” to your voice

17.01.2017 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>